In recent times, psychedelics based medicine developer Mind Medicine (MindMed) Inc (NASDAQ:MNMD) has come into considerable focus among investors and especially so after the stock was listed on NASDAQ not too long ago.
The stock was in the news yesterday after it emerged that there was insider action in Mind Medicine recently. It was revealed that the Chief Executive Officer of the company J.R. Rahn sold of a major share of his holdings in Mind Medicine.
According to the filings made by the company, the CEO sold off as much as $24.7 million worth of shares in Mind Medicine in a span of one week. That is a significant development and one that is going to be analyzed by investors for sure. After having sold off the chunk of his holdings, the CEO now has as many as 5.3 million options, only 1.7 million subordinate voting shares and 2 million restricted share units.
Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.